# Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer

> **NCT05706779** · PHASE2 · RECRUITING · sponsor: **Federation Francophone de Cancerologie Digestive** · enrollment: 30 (estimated)

## Conditions studied

- Colorectal Cancer
- BRAF V600E Mutation Positive

## Interventions

- **DRUG:** Encorafenib Oral Capsule + Cetuximab

## Key facts

- **NCT ID:** NCT05706779
- **Lead sponsor:** Federation Francophone de Cancerologie Digestive
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-13
- **Primary completion:** 2026-12-30
- **Final completion:** 2029-05-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05706779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05706779, "Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05706779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*